Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.51 |
| ▸ | EBP | Q15125 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192046 | 0.98 | SIGMAR1 (0.53) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL6923877 | 0.91 | SIGMAR1 (0.49) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL30411876 | 0.89 | SIGMAR1 (0.51) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL6929005 | 0.86 | KDM1A (0.51) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL27632864 | 0.86 | SIGMAR1 (0.49) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL4019674 | 0.82 | KDM1A (0.56) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL30460648 | 0.82 | KDM1A (0.56) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL28549243 | 0.80 | SIGMAR1 (0.56) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL11198839 | 0.80 | SIGMAR1 (0.56) | SIGMAR1EBPKDM1AMEN1KMT2A | |
| SCHEMBL28543963 | 0.80 | SIGMAR1 (0.56) | SIGMAR1EBPKDM1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2019-04-23 | — | — | US | disclosed |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2017-06-08 | — | — | US | disclosed |
| WO-2015193921-A1 | AN ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-12-23 | — | — | WO | disclosed |
| EP-0272534-A2 | 8-substituted 2-aminotetralins | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266481-B2 | Organocatalytic asymmetric synthesis of antidepressants | TPH1, NAT1, TPH2 | SIGMAR1 22/4885EBP 3635/4885KDM1A 528/4885 |
| US-20170158607-A1 | ORGANOCATALYTIC ASYMMETRIC SYNTHESIS OF ANTIDEPRESSANTS | TPH1, NAT1, TPH2 | SIGMAR1 22/4885EBP 3635/4885KDM1A 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.